TY - JOUR T1 - Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C JF - J Clin Gastroenterol Y1 - 2009 A1 - Chew, K.W. A1 - Allen, S.A. A1 - Taylor, L.E. A1 - Rich, J.D. A1 - Feller, E. KW - Adult KW - adverse effects KW - African Americans KW - Antibodies KW - Antiviral Agents KW - Biopsy KW - California KW - chronic HCV KW - Disease KW - drug therapy KW - Drug Therapy,Combination KW - ethnology KW - European Continental Ancestry Group KW - Follow-Up Studies KW - genetics KW - Genotype KW - genotype 1 KW - Goals KW - Guidelines KW - HCV KW - Hepacivirus KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - Hepatitis C,Chronic KW - Humans KW - interferon KW - Interferon Alfa-2b KW - Interferon-alpha KW - Liver KW - Lost to Follow-Up KW - Male KW - Medicine KW - Middle Aged KW - Patients KW - peginterferon KW - peginterferon alfa-2b KW - pegylated KW - pegylated interferon KW - Polyethylene Glycols KW - Prisoners KW - Prisons KW - Proteins KW - Recombinant Proteins KW - Research KW - Research Support KW - Retrospective Studies KW - Rhode Island KW - Ribavirin KW - Risk KW - Risk Factors KW - San Francisco KW - sustained virologic response KW - SVR KW - therapeutic use KW - therapy KW - Time KW - treatment KW - Treatment Outcome KW - Young Adult VL - 43 SP - 686-691 IS - 7 N1 - PMC2936234 ER -